ARP-1 Activators
ARP-1 activators constitute a group of chemicals that modulate the activity of ARP-1, a protein involved in cellular processes crucial for various physiological functions. These activators exert their effects through direct or indirect mechanisms, impacting specific signaling pathways to regulate ARP-1 activation. One prominent class of ARP-1 activators includes compounds that target the MAPK signaling pathway. BI-D1870 and PD98059, selective inhibitors of RSK and MEK, respectively, directly influence MAPK signaling, regulating downstream events that lead to ARP-1 activation. Additionally, SB203580, a p38 MAPK inhibitor, provides another avenue for ARP-1 activation by modulating the p38 MAPK-dependent pathways. Another set of ARP-1 activators involves compounds that interfere with cellular energy metabolism. PF-4708671, an AMPK inhibitor, indirectly activates ARP-1 by regulating cellular energy levels. This highlights the intricate connection between cellular energy status and ARP-1 activation.
Furthermore, compounds like CCT128930 and AZD8055 target mTOR and mTORC1, respectively, influencing ARP-1 activation through the mTOR-dependent pathways. These activators showcase the significance of mTOR-related signaling in ARP-1 regulation. Moreover, ARP-1 activators such as SL0101 and SB216763 operate through inhibition of CDK and GSK-3β, respectively, presenting indirect mechanisms for ARP-1 modulation. These compounds impact cell cycle progression and cellular processes related to ARP-1 activation. In summary, ARP-1 activators form a diverse class of chemicals with distinct modes of action, providing valuable tools for studying ARP-1 function and its implications in cellular physiology. Understanding the intricate network of pathways influenced by these activators opens avenues for exploring ARP-1's role in various biological processes and potential applications in research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BI-D1870 | 501437-28-1 | sc-397022 sc-397022A | 1 mg 5 mg | $92.00 $260.00 | 12 | |
Activates ARP-1 through inhibition of RSK (ribosomal S6 kinase) signaling. BI-D1870 is a selective RSK inhibitor that directly impacts the MAPK signaling pathway. By inhibiting RSK, BI-D1870 can modulate downstream events that lead to the activation of ARP-1, potentially influencing its cellular functions. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
Activates ARP-1 by inhibiting AMP-activated protein kinase (AMPK). PF-4708671 is an AMPK inhibitor that can indirectly impact ARP-1 by regulating cellular energy metabolism. By inhibiting AMPK, this compound may alter intracellular signaling cascades and create an environment conducive to ARP-1 activation. | ||||||
SL 0101-1 | 77307-50-7 | sc-204287 sc-204287A sc-204287B sc-204287C sc-204287D | 1 mg 10 mg 25 mg 50 mg 100 mg | $200.00 $353.00 $772.00 $1230.00 $2070.00 | 3 | |
Indirectly activates ARP-1 through inhibition of CDK (cyclin-dependent kinase) signaling. SL0101 is a selective CDK inhibitor that can modulate cell cycle progression. By inhibiting CDK, SL0101 may influence the phosphorylation events related to ARP-1 activation, providing an indirect mechanism for its regulation. | ||||||
CCT128930 | 885499-61-6 | sc-364459 sc-364459A | 5 mg 10 mg | $156.00 $292.00 | 2 | |
Activates ARP-1 by inhibiting mTOR (mammalian target of rapamycin) signaling. CCT128930 is an mTOR inhibitor that can impact ARP-1 through the regulation of mTOR-dependent pathways. By inhibiting mTOR, this compound may modulate downstream events leading to the activation of ARP-1, potentially influencing its cellular functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Indirectly activates ARP-1 by inhibiting MEK (mitogen-activated protein kinase kinase) signaling. PD98059 is a selective MEK inhibitor that can modulate the MAPK signaling pathway. By inhibiting MEK, PD98059 may influence downstream events related to ARP-1 activation, providing an indirect mechanism for its regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Activates ARP-1 by inhibiting p38 MAPK (mitogen-activated protein kinase) signaling. SB203580 is a selective p38 MAPK inhibitor that can impact ARP-1 through the regulation of p38-dependent pathways. By inhibiting p38 MAPK, this compound may modulate downstream events leading to the activation of ARP-1, potentially influencing its cellular functions. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
Indirectly activates ARP-1 through inhibition of GSK-3β (glycogen synthase kinase-3 beta) signaling. SB216763 is a selective GSK-3β inhibitor that can modulate cellular processes related to ARP-1 activation. By inhibiting GSK-3β, this compound may influence downstream events leading to the activation of ARP-1, providing an indirect mechanism for its regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Activates ARP-1 by inhibiting PI3K (phosphoinositide 3-kinase) signaling. LY294002 is a PI3K inhibitor that can impact ARP-1 through the regulation of PI3K-dependent pathways. By inhibiting PI3K, this compound may modulate downstream events leading to the activation of ARP-1, potentially influencing its cellular functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Indirectly activates ARP-1 through inhibition of JNK (c-Jun N-terminal kinase) signaling. SP600125 is a selective JNK inhibitor that can modulate cellular processes related to ARP-1 activation. By inhibiting JNK, this compound may influence downstream events leading to the activation of ARP-1, providing an indirect mechanism for its regulation. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
Activates ARP-1 by inhibiting PLK1 (polo-like kinase 1) signaling. BI2536 is a selective PLK1 inhibitor that can impact ARP-1 through the regulation of PLK1-dependent pathways. By inhibiting PLK1, this compound may modulate downstream events leading to the activation of ARP-1, potentially influencing its cellular functions. | ||||||